Biomarker

The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...

Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though...

If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...

IBD is linked to higher skeletal risk; early biochemical changes in Wnt-pathway proteins might identify bone impairment before DXA detects low bone density, potentially helping earlier risk stratification.

These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...

Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve...

Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...

Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...

Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.

Pyroptosis is a key inflammatory pathway that may drive or modulate IBD activity. Understanding and targeting it could lead to new treatments, but past trial setbacks mean patients should know translation is still...

Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.

Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...

A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...

This study tested a blood biomarker (zonulin) tied to gut barrier function and found no evidence of increased intestinal permeability in these Behçet syndrome patients, unlike in the Crohn’s disease group.

Multi-omics and AI approaches could improve biomarker discovery and predictive models that matter for earlier diagnosis and personalised treatment strategies in IBD, but practical use is limited today by data and...

This study uses transcriptomics, single‑cell data, and machine learning to nominate lactylation‑related genes as biomarkers and drug targets in ulcerative colitis, which could guide future biomarker or drug‑repurposing...

Blood platelet indices (PLR, MPV) are simple blood-test measures that may help detect IBD activity and show changes with biologic treatment. If validated, they could offer an inexpensive, noninvasive way to supplement...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.

This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...

A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.

Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers...

Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...

Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...

The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...

If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...

People with ulcerative colitis often face trial‑and‑error when starting advanced therapies. THAMES‑IBD aims to find biological and psychosocial markers that predict who will respond, which could eventually make treatment...

The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...

RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.

The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...

A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...

The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.

People with IBD commonly experience mood disorders; identifying shared molecular signals could help explain why and point to biomarkers or targets for research. This study proposes three genes linked to conserved...

A reliable blood biomarker that predicts relapse while a person with UC is in remission could help tailor monitoring intensity and treatment decisions.

A simple blood marker (LBP) that reflects bacterial exposure across the gut barrier was linked to disease severity and immune activity at diagnosis and during follow-up—especially in ulcerative colitis—so it might help...

Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...

If validated, early bedside ultrasound changes could let clinicians identify within days whether steroids or biologics are working, enabling faster treatment adjustments and potentially avoiding prolonged ineffective...

If confirmed, a pretreatment mucosal JAK‑dependent inflammatory signature could help predict who will respond to tofacitinib, potentially guiding therapy choice and avoiding ineffective treatment for people with...

Detecting molecular signs of IBD before symptoms could eventually allow earlier monitoring or preventive strategies, changing how and when people at risk are identified. For patients, this research points to hope that...

Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.

This study proposes three autophagy-related genes (APOL1, CCL2, IL24) as potential biomarkers that may help classify ulcerative colitis patients into subtypes with different immune environments, which could eventually...

This study links a neutrophil protein (ANXA3) to both ulcerative colitis and ischaemic stroke and suggests a compound (ginsenoside Rb1) can bind ANXA3 and reduce neutrophil hyperactivation in lab tests — a potential...

Relatives of people with IBD are at higher risk; this study aims to identify early markers or behaviors that predict who develops IBD so prevention or earlier diagnosis might become possible.

This review summarises the rapidly changing drug landscape for Crohn’s disease and ulcerative colitis, including newly approved biologics and small molecules and several emerging therapies that may affect future...

If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.

Understanding whether innate lymphoid cells retain ‘memory’ that drives psoriasis relapse could reveal biomarkers to monitor recurrence and suggest new therapeutic targets for patients with recurrent disease.

Oxidative stress may be a key driver of inflammation in IBD and could point to new biomarkers or adjunctive treatments (dietary changes, antioxidant strategies, or targeted pathways like Nrf2 and ferroptosis) that...

The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.

Circulating glycoprotein signals may help explain how systemic inflammation in IBD interacts with metabolic liver disease (MASLD). If validated, they could improve risk stratification for liver complications beyond...